BCK Partners Inc. Sells 339 Shares of Amgen Inc. (NASDAQ:AMGN)

by · The Cerbat Gem

BCK Partners Inc. decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 32.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 715 shares of the medical research company’s stock after selling 339 shares during the quarter. Amgen comprises approximately 0.1% of BCK Partners Inc.’s holdings, making the stock its 24th largest position. BCK Partners Inc.’s holdings in Amgen were worth $223,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. BankPlus Wealth Management LLC increased its holdings in Amgen by 3.3% during the 1st quarter. BankPlus Wealth Management LLC now owns 1,885 shares of the medical research company’s stock valued at $587,000 after purchasing an additional 61 shares in the last quarter. Crown Wealth Group LLC raised its stake in shares of Amgen by 5.6% in the 1st quarter. Crown Wealth Group LLC now owns 849 shares of the medical research company’s stock valued at $265,000 after purchasing an additional 45 shares during the period. Citizens National Bank Trust Department raised its stake in shares of Amgen by 0.7% in the 1st quarter. Citizens National Bank Trust Department now owns 9,414 shares of the medical research company’s stock valued at $2,933,000 after purchasing an additional 70 shares during the period. Stonebridge Financial Group LLC raised its stake in shares of Amgen by 7.2% in the 1st quarter. Stonebridge Financial Group LLC now owns 13,210 shares of the medical research company’s stock valued at $4,115,000 after purchasing an additional 886 shares during the period. Finally, KBC Group NV raised its stake in shares of Amgen by 20.6% in the 1st quarter. KBC Group NV now owns 292,344 shares of the medical research company’s stock valued at $91,080,000 after purchasing an additional 49,909 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research analyst reports. Wall Street Zen upgraded Amgen from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 18th. Piper Sandler reiterated an “overweight” rating and set a $328.00 price target on shares of Amgen in a report on Friday. Guggenheim began coverage on Amgen in a report on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 price objective for the company. Royal Bank Of Canada decreased their price objective on Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Finally, Johnson Rice set a $294.00 price target on shares of Amgen in a research report on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $307.82.

Check Out Our Latest Research Report on AMGN

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president now directly owns 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.69% of the stock is owned by corporate insiders.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $277.13 on Monday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.17 and a quick ratio of 0.88. The company’s 50-day moving average is $281.02 and its 200 day moving average is $286.19. The stock has a market capitalization of $149.02 billion, a P/E ratio of 25.29, a P/E/G ratio of 2.51 and a beta of 0.51.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.96 earnings per share. On average, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).